first generic glp 1 Canada approves version of Ozempic amid rising GLP-1 competition FDA Approves Generic Version of

Read More KEY INSIGHTS In 2026, Novo Nordisks patent on semaglutide will expire in several countries, including India and China

The DURATION-1 and DURATION-5 clinical trials, which directly compared exenatide BID (Byetta) to exenatide QW (Bydureon), reported better HbA1c level reduction for Bydureon [119, 120]

FDA Disclaimer : GLP BodyGuard is an educational tracking and estimation platform

"However, the most important group that we really want to address are the patients who have obesity alongside other comorbid conditions, such as type 2 diabetes, hypertension, obstructive sleep apnea and significant osteoarthritis," Anderson, who is also a board member of the Diabetes Leadership Council, told Fox News Digital